Project A 3-year open-label, exploratory, single arm study to describe long term changes in the visual system of patients…

Basic data

Title:
A 3-year open-label, exploratory, single arm study to describe long term changes in the visual system of patients with relapsing remitting multiple sclerosis (RRMS) on oral dimethyl fumarate“ (VISION)
Duration:
25/09/2015 to 31/07/2017
Abstract / short description:
Dimethyl fumarate is the first oral first-line MS-therapy assumed to have protective effects on neuronal cells. It is for example able to promote cytoprotective responses in cells by activating the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway.
By crossing the brain-blood-barrier, it is supposed that dimethyl fumarate might also have an effect on the ocular fundus and might therefore protect retinal ganglion cells and their axons from degeneration, irrespective of an acute optic neuritis in the initial MS phase.
This trial is performed to evaluate the neuroprotective effect of dimethyl fumarate in RRMS patients in an early phase.
Keywords:
neuroprotection
Neuroprotektion
multiple sclerosis
Multiple Sklerose
Dimethylfumarat
Optische Kohärenztomographie

Involved staff

Managers

University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine

Contact persons

University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Neurology with Focus on Neurovascular Diseases
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine

Funders

Ismaning, Bayern, Germany
Help

will be deleted permanently. This cannot be undone.